CAJ | 학술논문

分子标志物在乳腺癌的治疗中已经得到了广泛应用,细胞增殖标志物Ki-67的表达与乳腺癌的临床病理特征及预后相关联,并且在评估新辅助化疗及内分泌治疗的疗效方面具有重要的预测价值.Ki-67高表达可作为乳腺癌的不良预后因素,其与肿瘤的发展、转移和预后高度相关.
분자표지물재유선암적치료중이경득도료엄범응용,세포증식표지물Ki-67적표체여유선암적림상병리특정급예후상관련,병차재평고신보조화료급내분비치료적료효방면구유중요적예측개치.Ki-67고표체가작위유선암적불량예후인소,기여종류적발전、전이화예후고도상관.
Molecular markers have been widely used in the treatment of breast cancer. Cell proliferation markers Ki-67 antigen representing breast neoplasms proliferative activity is associated with clinic pathological features and prognosis and has an important predictive value in assessing the effect of neoadjuvant chemotherapy and endocrine therapy. High expression of Ki-67 is a bad prognostic factor of breast cancer, which is highly related to tumor progression, metastasis and prognosis.